文献速递肝病

OCE-205(选择性V1a受体混合激动-拮抗剂)治疗肝肾综合征-急性肾损伤:2期随机试验

OCE-205, a selective V1a receptor mixed agonist-antagonist, for the treatment of hepatorenal syndrome-acute kidney injury: A phase 2 randomized trial.
PubMed 文献 · Hepatology · 2026-04-08

这项2期随机双盲安慰剂对照剂量探索研究在北美23个中心开展,评估OCE-205治疗HRS-AKI的安全性和有效性。因替尔利加压素获批,研究提前终止。OCE-205组48.6%对安慰剂组30.0%达到主要终点(p=0.48),差异无统计学意义。OCE-205耐受性良好,无过度血管收缩或相关缺血/呼吸衰竭事件。

要点

  • OCE-205在HRS-AKI患者中耐受性良好,未观察到过度血管收缩或相关缺血/呼吸衰竭事件。
  • 主要终点(确认临床改善)OCE-205组48.6% vs 安慰剂组30.0%,差异无统计学意义(p=0.48)。
  • 研究因替尔利加压素获批而提前终止,样本量不足,把握度不够。

核心结论

  • OCE-205在所有剂量水平耐受性良好,无过度血管收缩或相关缺血/呼吸衰竭证据。
  • OCE-205具有可预测的封顶最大效应,在数值上改善更多HRS-AKI患者,但研究把握度不足以达到统计学显著性。
  • OCE-205作为新型HRS疗法具有有利的风险-获益特征,值得进一步研究。

研究设计与样本

  • 随机、双盲、安慰剂对照、剂量探索研究,在北美23个中心开展。
  • 患者接受OCE-205持续输注8、15、30或50 µg/h或安慰剂。
  • OCE-205组n=37,安慰剂组n=10;因替尔利加压素获批后研究提前终止。

主要发现

  • 主要终点(确认临床改善:sCr<1.5 mg/dL且绝对下降≥0.3 mg/dL持续2天)在OCE-205组为48.6%,安慰剂组为30.0%(Log-rank检验p=0.48,贝叶斯分析无统计学意义)。
  • 心动过缓是最常见不良事件(21.6% vs 0%),多数无症状、无需干预。
  • 未出现新的/非预期安全性发现,无缺血事件,无相关呼吸衰竭事件。
  • 基线特征:OCE-205组vs安慰剂组sCr 2.6 vs 2.3 mg/dL,MELD 27.9 vs 25.8,酒精相关肝硬化51.4% vs 60.0%。

关键数值与推荐

  • 主要终点定义:血清肌酐(sCr)<1.5 mg/dL且绝对下降≥0.3 mg/dL持续2天。
  • OCE-205剂量:8、15、30、50 µg/h持续输注。

临床怎么用

  • OCE-205在HRS-AKI中显示出可预测的封顶效应和良好的安全性,但当前证据尚不足以支持临床常规使用。
  • 需进一步开展更大规模研究以验证OCE-205对HRS-AKI的疗效。

局限性

  • 研究因替尔利加压素获批而提前终止,样本量小(OCE-205组37例,安慰剂组10例),把握度不足。
  • 主要终点差异未达统计学显著性(p=0.48)。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND AIMS: OCE-205 is a mixed agonist-antagonist selective for the vasopressin 1a (V1a) receptor with no vasopressin 2 (V2) receptor activity. Safety and efficacy of OCE-205 were evaluated in patients with hepatorenal syndrome-acute kidney injury (HRS-AKI). APPROACH AND RESULTS: A randomized, double-blind, placebo-controlled, dose-ranging study was conducted at 23 North American centers. Patients received a continuous infusion of OCE-205 at 8, 15, 30, or 50 µg/h or placebo. The primary endpoint was time to confirmed clinical improvement, defined as serum creatinine (sCr) <1.5 mg/dL with an absolute reduction of ≥0.3 mg/dL for 2 days. Following terlipressin's approval, this study was stopped early due to a lack of equipoise in conducting a placebo-controlled trial. Baseline characteristics between OCE-205 (n=37) versus placebo (n=10) groups were sCr 2.6 versus 2.3 mg/dL, MELD 27.9 versus 25.8, alcohol-associated cirrhosis 51.4% versus 60.0%. The primary endpoint was met in 48.6% versus 30.0% ( p =0.48 by Log-rank test and NS by Bayesian analysis). Bradycardia was the most common adverse event (21.6% vs. 0%). Most events were asymptomatic, requiring no intervention. No new/unexpected safety findings, no events of ischemia, and no related events of respiratory failure occurred. CONCLUSIONS: OCE-205 was well tolerated, with no evidence of excessive vasoconstriction or related events of ischemia or respiratory failure at any dose level. OCE-205 had a predictable, capped maximal efficacy that improved HRS-AKI in numerically more patients than placebo, though it was underpowered for statistical significance. OCE-205 warrants additional investigation as a novel HRS therapy with a favorable benefit-risk profile.

来源:Hepatology,查看原文。版权归原作者所有。

引用

  1. Allegretti AS, Cullaro G, Kwo P, et al. OCE-205, a selective V1a receptor mixed agonist-antagonist, for the treatment of hepatorenal syndrome-acute kidney injury: A phase 2 randomized trial. Hepatology. 2026. PMID: 41950496. doi:10.1097/HEP.0000000000001765

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。